Phase 2b Data Suggest ReVision Therapeutics, Inc.'s Oral Fenretinide (RT-101) Slows Lesion Growth, Preserves Vision and Reduces Incidence of Neovascularization in Geographic Atrophy Patients
10/18/2010 7:09:32 AM
More...
|
ReVision Therapeutics, Inc.'s Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial
9/1/2010 8:17:43 AM
More...
|